Magenta Therapeutics

Magenta agrees to reverse merger with Dianthus after setbacks
Magenta agrees to reverse merger with Dianthus after setbacks
BioPharma Dive
Magenta Therapeutics
M&A
Dianthus Therapeutics
autoimmune disease
Flag link:
BioSpace Layoff Tracker 2023: Grifols, Frequency, Eliem and More Cut Staff
BioSpace Layoff Tracker 2023: Grifols, Frequency, Eliem and More Cut Staff
BioSpace
layoffs
Grifols
Frequency Therapeutics
Eliem Therapeutics
Aligos Therapeutics
Thermo Fisher Scientific
Magenta Therapeutics
Eisai
Amgen
Y-mAbs Therapeutics
Century Therapeutics
Elevation Oncology
Calithera Biosciences
Editas Medicine
Verily
Abzena
Flag link:
Magenta's C-suite heads out the door with 85% of staff as closing process gets underway
Magenta's C-suite heads out the door with 85% of staff as closing process gets underway
Fierce Biotech
Magenta Therapeutics
layoffs
executives
Flag link:
Days after halting leukemia drug, Magenta moves to close its doors
Days after halting leukemia drug, Magenta moves to close its doors
Fierce Biotech
Magenta Therapeutics
leukemia
Flag link:
Patient death spurs trial halt for Magenta Therapeutics
Patient death spurs trial halt for Magenta Therapeutics
Endpoints
Magenta Therapeutics
MGTA-117
clinical trials
patient deaths
AML
myelodysplastic syndrome
Flag link:
Why The Magenta Therapeutics (MGTA) Stock Plummeted Over 50%
Why The Magenta Therapeutics (MGTA) Stock Plummeted Over 50%
Pulse 2.0
Magenta Therapeutics
clinical trials
MGTA-117
AML
myelodysplastic syndrome
Flag link:
Big Pharma Is Going Holiday Shopping. Who's Next?
Big Pharma Is Going Holiday Shopping. Who's Next?
Motley Fool
Big Pharma
M&A
ChemoCentryx
Epizyme
Magenta Therapeutics
Flag link:
Magenta Down After FDA Places Clinical Hold on IND for AML/MDS Drug
Magenta Down After FDA Places Clinical Hold on IND for AML/MDS Drug
BioSpace
Magenta Therapeutics
AML
MDS
FDA
clinical hold
MGTA-117
Flag link:
Magenta's R&D head hits the exit just weeks after reading out mid-stage data for lead therapy, eyeing clinic for another
Magenta's R&D head hits the exit just weeks after reading out mid-stage data for lead therapy, eyeing clinic for another
Endpoints
Magenta Therapeutics
stem cells
stem cell transplant
clinical trials
Flag link:
Magenta, Beam partner to explore use of antibody-based conditioning drug for gene therapies
Magenta, Beam partner to explore use of antibody-based conditioning drug for gene therapies
MedCity News
Magenta Therapeutics
Beam Therapeutics
MGTA-117
gene therapy
sickle cell disease
beta thalassemia
Flag link:
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
Yahoo/Benzinga
ASH2019
Roche
Bristol-Myers Squibb
Acadia Pharmaceuticals
Biogen
Cassava Sciences
Alector
GW Pharma
Magenta Therapeutics
Fortress Biotech
Mustang Bio
Bluebird Bio
Flag link:
2 Small-Cap Biotechs That Soared Last Week
2 Small-Cap Biotechs That Soared Last Week
Motley Fool
Magenta Therapeutics
Molecular Templates
gene therapy
CAR-T
cancer
Flag link:
Magenta Therapeutics presents updated Phase 2 clinical data on MGTA-456 cell therapy
Magenta Therapeutics presents updated Phase 2 clinical data on MGTA-456 cell therapy
Pharmaceutical Business Review
Magenta Therapeutics
cell therapy
clinical trials
MGTA-456
inherited metabolic disorders
metabolic disorders
Flag link:
Magenta stem cell transplant drug seems to work, but is it safe?
Magenta stem cell transplant drug seems to work, but is it safe?
Fierce Biotech
Magenta Therapeutics
MGTA-456
clinical trials
stem cells
Flag link:
Bio IPO Madness: Six Biotech Startups Raise $568M in 24 Hours
Bio IPO Madness: Six Biotech Startups Raise $568M in 24 Hours
Xconomy
biotech
IPOs
Eidos Therapeutics
Avrobio
XERIS
Aptinyx
Kezar Life Sciences
Magenta Therapeutics
Flag link:
Three Biotechs Announced IPOs Friday
Three Biotechs Announced IPOs Friday
BioSpace
IPOs
Autolus
Magenta Therapeutics
MeiraGTx
Flag link:
Magenta Therapeutics Launches $100 Million IPO
Magenta Therapeutics Launches $100 Million IPO
CP Wire
Magenta Therapeutics
IPOs
Flag link:
Magenta Therapeutics Launches $100 Million IPO
Magenta Therapeutics
Flag link:
Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it
Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it
Endpoints
Magenta Therapeutics
Novartis
stem cells
HSC835
Flag link: